Increased fertility in bovine species

Patent metadata

Field	Value
Publication number	US-10933131-B2
Application number	US-201716320256-A
Country	US
Kind code	B2
Filing date	Jul 25, 2017
Priority date	Jul 26, 2016
Publication date	Mar 2, 2021
Grant date	Mar 2, 2021

Abstract

The present invention relates to compositions and methods for immunomodulation which are effective for increasing conception rate in cows.

First claim

What is claimed:

1. A method of increasing the conception rate in one or more cows comprising administering to the cows an effective amount of an immunomodulator composition, wherein the immunomodulator composition comprises: a cationic liposome delivery vehicle, wherein the liposome delivery vehicle comprises one or more pairs of lipids selected from the group consisting of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylanimonium chloride (DOTMA) and cholesterol; N-[1-(2,3-dioleoyloxy)propyl]N,N,N-trimethylammonium chloride (DOTAP) and cholesterol; 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl) imidazolinium chloride (DOTIM) and cholesterol; and dimethyldioctadecylammonium bromide (DDAB) and cholesterol and an isolated bacterially obtained nucleic acid molecule that does not code for an immunogen and has at least 90% sequence identity with the sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

2. The method of claim 1 , wherein said nucleic acid molecule comprises at least one immunostimulatory CpG motif and at least one non-immunostimulatory CpG motif.

3. The method of claim 1 , wherein the Liposome delivery vehicle comprises one or more lipids selected from the group consisting of multilamellar vesicle lipids and extruded lipids.

4. The method of claim 1 , wherein the nucleic acid molecule comprises SEQ ID NO: 1.

5. The method of claim 1 , wherein the nucleic acid molecule comprises SEQ ID NO: 2.

6. The method claim 1 wherein the immunomodulator composition further comprises a biological agent.

7. The method of claim 6 , wherein the biological agent is selected from the group consisting of immune enhancer proteins, immunogens, vaccines, antimicrobials or any combination thereof.

8. The method of claim 1 , wherein the administering is selected from the group consisting of intravenously, intramuscularly, intradermal, intraperitoneal, subcutaneously, by spray-aerosol, orally, intraocularly, intracheally, and intranasal.

9. The method of claim 1 wherein the immunomodulator composition further comprises comprising a pharmaceutically acceptable earner.

10. The method of claim 1 wherein the conception rate in cows increases relative to the conception rate in a control population as measured by a p-value of ≤0.05.

Assignees

• Bayer Animal Health Gmbh

Inventors

• Nickell Jason
• Keil Daniel
• Abraham Albert
• Tully Warren
• Olde Riekerink Richard Gerhardus Martinu
• Settje Terry
• Vickers Leland
• Nibbelink Stuart

Classifications

• A61P15/08

  for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis · CPC title

• A61K2039/55561

  CpG containing adjuvants; Oligonucleotide containing adjuvants · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61K9/1272

  comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543}) · CPC title